Eurofins BioPharma Services Newsletter 42 - Fall 2025
ARTICLES:
- Eurofins’ GLP 1 agonist multiplex testing enables rapid, data-driven decision-making and improves success rates in treating complex diseases
- Achieve speed and sustainability with the adoption of newer rapid microbiological methods
- Using secondary pharmacology panels to predict clinical safety risks
- Environmental Risk Assessment in the pharma sector: Navigating regulatory frameworks and implementation strategies
- The crucial role of high-fidelity spent media analytics in AI-driven biopharmaceutical R&D and production
- Eurofins PSS expands sites into Sweden, continuing growth across Europe
- Eurofins Viracor BioPharma Services relocates to new state-of-the-art facility
Download the PDF version of pharma newsletter N°42